We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
HTG Introduces Testing Method for RNA in Fixed Tissue Samples
Product News

HTG Introduces Testing Method for RNA in Fixed Tissue Samples

HTG Introduces Testing Method for RNA in Fixed Tissue Samples
Product News

HTG Introduces Testing Method for RNA in Fixed Tissue Samples


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "HTG Introduces Testing Method for RNA in Fixed Tissue Samples"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

HTG, Inc. has announced the availability of a new in situ testing method for gene expression in formalin-fixed, paraffin-embedded (FFPE) tissue samples.

Using HTG’s qNPA™ (quantitative Nuclease Protection Assay) technology, researchers can quantitate RNA expression for up to 16 targets simultaneously in FFPE tissue sections without the need for extraction or target amplification.

With conventional methods it has been challenging for researchers to analyze fixed tissue samples and yield useful information because it is difficult to extract RNA from fixed sample blocks for several reasons.

Formalin, the most common fixative, is excellent at preserving structure but the fixation process also causes a series of crosslinks to form, making molecular assays difficult to run.

Second, the quality of RNA quickly deteriorates over time. Both factors make it difficult to extract gene targets for molecular testing, secure accurate information and eliminate false positives.

HTG’s qNPA technology allows researchers to simply lyse the tissue section, incubate the qNPA probes and then detect the levels of up to 16 different RNA targets simultaneously.

Whole assay CVs are 10 percent or less and the qNPA method has been tested successfully on tissue blocks up to 15 years old making retrospective studies feasible.

The ArrayPlate qNPA technology provides the absolute sensitivity to measure any gene desired, including low abundant genes.

Instead of studying one gene at a time, researchers are also able to select a set of genes for simultaneous evaluation, a critical step in identifying the most promising drug compounds to treat complex, multi-factorial diseases.

“Until now, there has not been an effective means to analyze RNA in fixed tissue samples,” said Bruce Seligmann, CSO, HTG. “HTG’s qNPA multiplexed technology offers researchers a quick, easy and reliable method to examine RNA stored in fixed tissue samples.

HTG’s method is so sensitive and precise that the age of the tissue block is no longer a factor and retrospective studies can be performed to identify changes in diseases or patients over time.”

Advertisement